Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors

Journal of Cancer Research and Therapeutics

Volumn 3, Issue 3, 2007, Pages 150-152

  Attili, Venkata ^a   Chandra, Rama ^a   Anupama, G ^a   Loknath, D ^a   Bapsy, P ^a   Dadhich, Hemant ^a   Babu, Govind ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

And cisplatin; Bleomycin; Cost effectiveness analysis; Etoposide; Metastatic germ cell tumors; VIP

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HISTOLOGY; HUMAN; MALE; METASTASIS; NEUROPATHY; NEUTROPENIA; PROGNOSIS; STRATIFICATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 37349028968     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.37407     Document Type: Article

References (7)

1. Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, et al. Intensive induction-sequential chemotherapy with BOP/VIPB compared with treatment with BEP/EP for poor-prognosis metastatic non-seminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692-701.
2. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
3. Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours: Preliminary results of a French randomized trial. Eur Urol 1993;23:213-8.
4. Kaye S, Mead G, Fossa M. An MRC/EORTC randomized trial in poor risk metastatic teratoma comparing BEP to BOP-VIP. Proc Am Soc Oncol 1995;14:246.
5. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-93.
6. Stoter G, Sleijfer D, Schrnagel J. BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer. Proc Am Soc Oncol 1993;12:232.
7. Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986;4:28-34.